FTC told to examine biologic pay-for-delay

The US Federal Trade Commission (FTC) should “examine whether makers of biologic medicines are using strategies like ‘pay for delay’ to hinder or delay biosimilars from entering the market”, according to an open letter from US Senators Chuck Grassley and Amy Klobuchar to the US antitrust regulator.